SPL 0.00% 8.9¢ starpharma holdings limited

In term of nanomedicine, the main competitor is Abraxane...

  1. 54 Posts.
    In term of nanomedicine, the main competitor is Abraxane (https://en.wikipedia.org/wiki/Protein-bound_paclitaxel). Abraxane now showed the more advantages in stable compound, which is less side effects and more effect.
    The basics of platform of Abraxane is different to dendrimer. Abraxane is based on albumin-bound particle, the whole structure will less stable to support Her2 or any cells signals receptors. I think that is the reason Abraxane is independence outside big pharma worlds.
    If SPL can prove the advantages of  dendrimer-drug, we will be crushed and acquired by big boys pharma at any cost.
    The most important results of HER2-DEP is more effects than current HER2-antibody therapy.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
8.9¢
Change
0.000(0.00%)
Mkt cap ! $36.67M
Open High Low Value Volume
9.0¢ 9.1¢ 8.7¢ $257.5K 2.884M

Buyers (Bids)

No. Vol. Price($)
3 119243 8.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 60378 1
View Market Depth
Last trade - 16.10pm 26/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.